George F. Tidmarsh, President, CEO, 10% Owner, & Secretary, of La Jolla Pharmaceuticals, bought 3,000 shares of La Jolla (Stock Symbol: Enter LJPC) at $7.25 per share for a total amount of $21.8 thousand on February 07, 2014.
La Jolla is headquartered in San Diego, CA. On 02/12/2014, La Jolla Pharmaceutical Company formed a scientific advisory board. On 11/08/2013, La Jolla announced its latest quarterly results. “Our third quarter included the closing of a $10 million financing led by fundamental institutional investors accompanied by a capital restructuring for La Jolla. This financing gives us cash sufficient to progress three drugs through clinical proof-of-concept over the next eighteen months,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “The La Jolla team is focused on initiation of a Phase 1 trial with LJPC-501, finishing enrollment of our Phase 2 clinical trial of GCS-100 in chronic kidney disease and continuing to build our pipeline.”
According to Capital IQ, La Jolla has a market cap of $36.38 million, an enterprise value of $25.68 million, and trailing 12 month revenues of N/A. La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The companys products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
George Tidmarsh’s most recent annual compensation from La Jolla is a salary of $226,462, $30,347,600 in other compensation, and a total compensation of $30,644,900. Mr. Tidmarsh is 53 years old. According to his biography, Dr. George F. Tidmarsh, M.D., Ph.D., has been President, Chief Executive Officer, Secretary, Director of La Jolla Pharmaceutical Co., since January 2012 . Prior to joining the Company, Dr. Tidmarsh was the Chief Executive Officer of Solana Therapeutics, Inc. since August 2011. Dr. Tidmarsh also served as Senior Vice President and Chief Scientific Officer of Spectrum Pharmaceuticals, Inc. from July 2010 to July 2011. He has been an Associate Professor of Neonatology at Stanford University School of Medicine since October 2010, founded and was the Chief Executive Officer of Metronome Therapeutics, Inc. from March 2006 to July 2010 and founded and was the Chief Executive Officer of Horizon Pharma, Inc. from September 2005 to July 2008. Mr. Tidmarsh currently serves on the board of Anavex Life Sciences Corp., a biopharmaceutical company. All stories in DailyStocks.com are for informational purposes only.
This is NOT a stock recommendation.
This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.